STOCKS TELEGRAPH

Tag: Cellectis

  • Cellectis (CLLS) Stock Is Skyrocketing After A Collaboration Deal

    Cellectis (CLLS) Stock Is Skyrocketing After A Collaboration Deal

    Cellectis S.A. (NASDAQ: CLLS) is experiencing an extraordinary surge in its stock price, soaring by an impressive 192.01% to reach $2.8150. That is also accompanied by an exceptional trading volume of over 52 million Cellectis shares traded as of the last check during current session. This remarkable upturn of CLLS stock in current trading is primarily attributed to strategic collaborations and investments.

    Cellectis recently announced its partnership with AstraZeneca, marked by a Joint Research Collaboration Agreement and an initial equity investment of $80 million. Cellectis also signed a memorandum of understanding (the “MOU”) with AstraZeneca relating to an additional equity investment of $140M.

    CLLS primarily entered into the agreement to accelerate the development of cutting-edge therapeutics in areas of significant unmet medical need, including oncology, immunology, and rare diseases. AstraZeneca will harness Cellectis’ proprietary gene editing technologies and manufacturing capabilities to create novel cell and gene therapy candidates.

    This collaboration allocates 25 genetic targets exclusively to AstraZeneca, with the potential to explore up to 10 candidate products for development. AstraZeneca retains the option for a global exclusive license for these candidates, exercisable prior to submitting an Investigational New Drug (IND) application. Under the Collaboration Agreement, AstraZeneca will fund Cellectis’ research costs and provide an upfront payment of $25 million.

    Additionally, Cellectis stands to receive an Investigational New Drug (IND) option fee, along with milestone payments linked to development, regulatory approvals, and sales achievements, ranging from $70 million to $220 million for each of the 10 candidate products, along with structured royalty arrangements.

    A condition of this collaboration is AstraZeneca’s $80 million equity investment in Cellectis, involving the acquisition of 16,000,000 ordinary shares at a price of $5.00 per share. These newly issued shares, authorized by Cellectis’ board of directors, are scheduled for settlement and delivery on November 6, 2023.

    This investment grants AstraZeneca approximately 22% of Cellectis’ share capital and 21% of its voting rights. Moreover, AstraZeneca gains the right to nominate a non-voting observer on Cellectis’ board of directors and to participate proportionally in Cellectis’ future share offerings.

  • Cellectis (CLLS) hires HR veteran as Executive Vice President, Chief Human Resources Officer

    Cellectis (Nasdaq: CLLS), a biopharmaceutical firm, today confirmed the appointment of Kyung Nam-Wortman as Chief Human Resources Officer and Executive Vice President of Cellectis. Also joining the Company’s Executive Committee is Ms. Nam-Wortman, who will be based in the New York office of Cellectis.

    Ms. Nam-Wortman will work closely with Dr. Choulika and the executive teams in her new position at Cellectis to ensure that the organization progresses the strategy through the recruiting and retaining of talented people. She will also focus on further cultivating and strengthening the diverse and multicultural community of Cellectis while maximizing the role of the human resource of the organization.

    Ms. Nam-Wortman joins Cellectis from Achillion, where she worked as Senior VP, Head of HR, Head of IT, Facilities, and Internal Communications.  She was responsible for managing the strategic and organizational aspects of the above roles at Achillion.

    Cellectis (Nasdaq: CLLS), a biopharmaceutical firm, today confirmed the appointment of Kyung Nam-Wortman as Chief Human Resources Officer and Executive Vice President of Cellectis. Also joining the Company’s Executive Committee is Ms. Nam-Wortman, who will be based in the New York office of Cellectis.

    Ms. Nam-Wortman will work closely with Dr. Choulika and the executive teams in her new position at Cellectis to ensure that the organisation progresses the strategy through the recruiting and retaining of talented people. She will also focus on further cultivating and strengthening the diverse and multicultural community of Cellectis, while maximising the human resources role of the organisation.

    Kyung Nam-Wortman joins Cellectis from Achillion, where she worked as Senior Vice President, Head of HR, Head of IT, Facilities and Internal Communications.  She was responsible for managing the strategic and organisational aspects of the above roles at Achillion.

    Ms. Nam-Wortman served as VP and Head of Global Talent and Corporate Capacity at Zoetis prior to her time at Achillion, where she helped spin-off of the animal health business unit of Pfizer via its IPO and was key player for standing up the international talent management role of Zoetis to boost the development of the sector worldwide. She has held numerous major positions in HR with Pfizer’s company groups, branches, and domestic and global management functions.

    Ms. Nam-Wortman has 14 years of expertise in the consultancy field focusing on strategic and organisational change management from Delta Consulting Group and IBM, in addition to her success with biotech/biopharma.

    After completing her bachelor’s degree in marketing from the New York University Stern School of Business Ms. Nam-Wortman did her MS in Human Resources Management/Organizational Growth from the New School of Social Research’s

    Cellectis (Nasdaq: CLLS), a biopharmaceutical firm, today confirmed the appointment of Kyung Nam-Wortman as Chief Human Resources Officer and Executive Vice President of Cellectis. Also joining the Company’s Executive Committee is Ms. Nam-Wortman, who will be based in the New York office of Cellectis.

    Ms. Nam-Wortman will work closely with Dr. Choulika and the executive teams in her new position at Cellectis to ensure that the organization progresses the strategy through the recruiting and retaining of talented people. She will also focus on further cultivating and strengthening the diverse and multicultural community of Cellectis while maximizing the role of the human resource of the organization.

    Ms. Nam-Wortman joins Cellectis from Achillion, where she worked as Senior Vice President, Head of HR, Head of IT, Facilities, and Internal Communications.  She was responsible for managing the strategic and organizational aspects of the above roles at Achillion.

    Kyung Nam-Wortman served as VP and Head of Global Talent and Corporate Capacity at Zoetis prior to her time at Achillion, where she helped spin-off of the animal health business unit of Pfizer via its IPO and was a key player for standing up the international talent management role of Zoetis to boost the development of the sector worldwide.

    Ms. Nam-Wortman has 14 years of expertise in the consultancy field focusing on strategic and organizational change management from Delta Consulting Group and IBM, in addition to her success with biotech/biopharma.

    After completing her bachelor’s degree in marketing from the New York University SternSchool of Business Ms. Nam-Wortman did her MS in Human ResourcesManagement/Organizational Growth from the New School of Social Research’s.

    MS. Nam-Wortman served as VP and Head of Global Talent and Corporate Capacity at Zoetis prior to her time at Achillion, where she helped spin-off the animal health business unit of Pfizer via its IPO and was a key player for standing up the international talent management role of Zoetis to boost the development of the sector worldwide. She has held numerous major positions in HR with Pfizer’s company groups, branches, and domestic and global management functions.

    Ms. Nam-Wortman has 14 years of expertise in the consultancy field focusing on strategic and organizational change management from Delta Consulting Group and IBM, in addition to her success with biotech/biopharma.

    After completing her bachelor’s degree in marketing from the New York University Stern School of Business Ms. Nam-Wortman did her MS in Human Resources Management/Organizational Growth from the New School of Social Research’s.